Inspire Medical Systems Announces CFO Departure, Sets 2025 Revenue Guidance

Inspire Medical Systems announced the departure of its CFO, Rick Buchholz, effective December 31, 2025. Buchholz will remain in a financial advisory role through February 28, 2026. The company is reaffirming its 2025 guidance with revenue expected between $900 and $910 million, gross margin between 84% and 86%, and diluted net income per share between $0.40 and $0.50. An active search is underway to identify the next CFO.

Inspire Medical Systems (NYSE: INSP), a leading medical technology company focused on sleep apnea solutions, has announced the departure of its Chief Financial Officer (CFO), Rick Buchholz, effective December 31, 2025. Buchholz will continue in a financial advisory role until February 28, 2026, to ensure a smooth transition [1].

During his tenure since 2014, Buchholz played a pivotal role in the company's growth, helping to achieve significant milestones including revenue growth from $4 million to over $800 million in 2024, successful IPO completion, and reaching profitability. The company has reaffirmed its 2025 guidance, projecting revenue of $900 to $910 million, gross margin of 84% to 86%, and diluted EPS of $0.40 to $0.50 [1].

The departure of Buchholz marks a new chapter for Inspire Medical Systems, which is actively searching for its next CFO. The company has a strong financial track record and a promising pipeline of innovative, minimally invasive solutions for patients with obstructive sleep apnea [1].

References:
[1] https://www.stocktitan.net/news/INSP/inspire-medical-systems-inc-announces-departure-of-chief-financial-4d0tv9i76al8.html